Gastroesophageal reflux disease affects roughly 1 in 5 American adults every week, and that number rises sharply with body weight. If you’ve been carrying extra pounds and dealing with heartburn that won’t quit, the two conditions are linked in ways most people don’t realize. This guide walks through what GERD really is, why obesity makes it worse, and how weight loss (including GLP-1 medications) fits into modern treatment.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey, and you can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
GERD is gastroesophageal reflux disease, the chronic form of acid reflux.<\/strong> It happens when stomach contents flow backward into the esophagus often enough to cause symptoms or damage tissue. Occasional reflux is normal. GERD is when it becomes a pattern, usually two or more episodes per week, or when it causes complications like esophagitis, strictures, or Barrett’s esophagus.<\/p>\n Quick Answer: About 20% of US adults have GERD symptoms weekly, per El-Serag’s 2014 review in Gut.<\/p>\n The classic symptoms are heartburn (a burning sensation behind the breastbone) and regurgitation (sour or bitter liquid rising into the throat). But GERD can also show up as chronic cough, hoarseness, throat clearing, dental erosion, or asthma-like wheezing. Doctors call these atypical or extraesophageal symptoms, and they’re often missed for years.<\/p>\n El-Serag’s 2014 systematic review in Gut put weekly GERD prevalence at 18 to 28% in North America. That’s tens of millions of people. The Nurses’ Health Study tracked over 10,000 women and found weekly heartburn in roughly 22%. Rates have risen steadily since the 1990s, tracking obesity rates almost perfectly.<\/p>\n The lower esophageal sphincter (LES) is a ring of muscle where the esophagus meets the stomach.<\/strong> Its job is to open when you swallow and stay shut the rest of the time. GERD develops when that valve fails or relaxes inappropriately.<\/p>\n Three main mechanisms drive most GERD:<\/p>\n Transient LES relaxations.<\/strong> The LES briefly opens when it shouldn’t, usually after meals. These transient relaxations are the single biggest driver of reflux episodes in people with normal LES pressure.<\/p>\n Hypotensive LES.<\/strong> The valve itself is weak, with resting pressure too low to keep stomach contents down. This is more common in severe or longstanding disease.<\/p>\n Hiatal hernia.<\/strong> Part of the stomach pushes up through the diaphragm into the chest cavity. This disrupts the natural anti-reflux geometry. Roughly half of people with GERD have a hiatal hernia, and the bigger the hernia, the worse the reflux tends to be.<\/p>\n Stack increased intra-abdominal pressure on top of any of these and you’ve got a recipe for chronic reflux. Which brings us to obesity.<\/p>\n Hampel’s landmark 2005 meta-analysis in the Annals of Internal Medicine pulled together nine studies and found a clear dose-response relationship: as BMI climbs, GERD risk climbs with it.<\/strong> Compared to normal-weight adults, people with a BMI between 25 and 30 had about 1.4 times the risk. BMI over 30 brought 1.9 times. Severe obesity pushed the risk even higher.<\/p>\n The mechanisms are mechanical and hormonal:<\/p>\n The connection isn’t subtle. Roughly 70% of patients in tertiary GERD clinics have a BMI above 25.<\/p>\n Yes, and the evidence is solid.<\/strong> Singh’s 2013 meta-analysis in Obesity Reviews looked at multiple intervention studies and concluded that weight loss produces dose-dependent improvements in GERD symptoms and esophageal acid exposure. The threshold that consistently shows up is roughly 10% of body weight, though some patients respond to less.<\/p>\n Jacobson’s 2006 study in the New England Journal of Medicine followed over 10,000 women and found that even modest BMI reductions cut heartburn frequency. Women who lost more than 3.5 BMI units had a 40% reduction in frequent heartburn risk.<\/p>\n Bariatric surgery data drives this point home. Roux-en-Y gastric bypass essentially cures GERD in most patients because it diverts acid-producing stomach away from the esophagus. Sleeve gastrectomy, in contrast, often makes reflux worse because the narrow gastric tube generates high intraluminal pressure.<\/p>\n This is where things get genuinely complicated.<\/strong> GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss, which should improve GERD over time. But they also slow gastric emptying, which can make reflux worse in the short term.<\/p>\n Lim’s 2024 systematic review in journals tracking GLP-1 GI effects found mixed reflux outcomes. Some patients on semaglutide reported new or worsened heartburn, especially in the first few months when gastric retention is most pronounced. Others saw GERD improve as weight came down.<\/p>\n The American Society of Anesthesiologists issued 2023 guidance recommending GLP-1s be held before elective procedures requiring sedation, specifically because of retained gastric contents and aspiration risk. That alone tells you the gastric-emptying effect is real.<\/p>\n Practical implication: if you have GERD and start a GLP-1, expect a possible rough patch. Eat smaller meals, don’t lie down for at least 3 hours after eating, and discuss adding or continuing acid suppression with your prescriber. Most patients who push through find their reflux improves substantially as they lose weight.<\/p>\n The 2022 ACG (American College of Gastroenterology) guideline lays out a clear treatment ladder.<\/strong><\/p>\n These come first for everyone:<\/p>\n H2 receptor antagonists (H2RAs).<\/strong> Famotidine is the workhorse. Available over the counter, it cuts acid production by blocking histamine receptors on parietal cells. Good for mild or intermittent symptoms. Tachyphylaxis (declining effect with continuous use) is a known issue.<\/p>\n Proton pump inhibitors (PPIs).<\/strong> Omeprazole, esomeprazole, pantoprazole, lansoprazole, and rabeprazole. These shut down acid production at the proton pump itself and produce far stronger acid suppression than H2RAs. They’re first-line for erosive esophagitis, severe symptoms, or anyone failing H2RAs. Take 30 to 60 minutes before the first meal of the day for best effect.<\/p>\n Alginates.<\/strong> Gaviscon and similar products form a foam raft on top of stomach contents, physically blocking reflux. Useful as add-on therapy, especially for postprandial breakthrough.<\/p>\n Prokinetics.<\/strong> Metoclopramide and similar drugs speed gastric emptying. Side effect profiles (especially neurological) limit their use.<\/p>\n PPIs are among the most-prescribed medications in the world, with tens of millions of users.<\/strong> Concerns about long-term use have generated headlines, but the actual evidence is mixed.<\/p>\n Likely real, modest concerns:<\/strong><\/p>\n Probably overstated:<\/strong><\/p>\n The ACG 2022 guideline notes that for most patients, PPI benefits clearly outweigh risks. But periodic reassessment makes sense. If symptoms have improved (often because of weight loss), trying to step down to H2RAs or as-needed dosing is reasonable.<\/p>\n Anti-reflux surgery is for patients with confirmed GERD who don’t respond adequately to medication, can’t tolerate PPIs, or want off long-term acid suppression.<\/strong> Confirmed means objective testing, usually pH monitoring or impedance testing, plus endoscopy.<\/p>\n Nissen fundoplication.<\/strong> The classic operation. The surgeon wraps the upper stomach (fundus) 360 degrees around the lower esophagus to reinforce the LES. Done laparoscopically. Excellent symptom control but can cause dysphagia, bloating, and inability to belch.<\/p>\n Toupet fundoplication.<\/strong> A 270-degree partial wrap. Lower side-effect profile but slightly less reflux control than Nissen.<\/p>\n LINX device.<\/strong> A magnetic sphincter augmentation. A bracelet of magnetic beads goes around the LES, allowing food to pass with swallowing pressure but resisting reflux. Less invasive recovery, fewer wrap-related side effects.<\/p>\n Transoral incisionless fundoplication (TIF).<\/strong> Done through the mouth without external incisions. Less effective than surgical fundoplication but a reasonable option for select patients.<\/p>\n Bariatric surgery.<\/strong> For obese patients with GERD, Roux-en-Y gastric bypass is often the right answer because it addresses both problems and produces durable reflux control. Sleeve gastrectomy generally worsens GERD and is usually avoided in patients with significant baseline reflux.<\/p>\n Chronic GERD can damage the esophageal lining, sometimes triggering metaplastic change called Barrett’s esophagus.<\/strong> Barrett’s is a precancerous condition that raises the risk of esophageal adenocarcinoma roughly 30-fold compared to the general population. The absolute risk is still low (maybe 0.1 to 0.5% per year), but esophageal adenocarcinoma is one of the deadliest cancers.<\/p>\n The ACG recommends screening endoscopy for patients with chronic GERD plus multiple risk factors:<\/p>\n If Barrett’s is found, surveillance endoscopy follows on an interval based on dysplasia status. High-grade dysplasia is treated with endoscopic eradication (radiofrequency ablation or endoscopic mucosal resection).<\/p>\n Most patients with obesity and GERD do best with a layered approach:<\/p>\n Roughly a third of GERD patients have symptoms beyond classic heartburn.<\/strong> These atypical presentations are often missed for years because patients and clinicians don’t connect the dots.<\/p>\n Chronic cough.<\/strong> GERD is one of the top three causes of chronic cough in adults, alongside asthma and postnasal drip. The cough is often dry, worse at night or after meals, and doesn’t respond to typical cough treatments. Empiric PPI trial of 8 to 12 weeks is reasonable diagnostic and therapeutic step.<\/p>\n Hoarseness and laryngitis.<\/strong> Reflux of acidic and non-acidic gastric contents into the larynx can cause chronic hoarseness, throat clearing, and sensation of a lump in the throat (globus). ENT evaluation often shows posterior laryngitis on laryngoscopy. The association is real but not every laryngitis is reflux-related.<\/p>\n Asthma.<\/strong> GERD worsens asthma in many patients, and asthma medications can worsen GERD. Patients with poorly-controlled asthma despite optimal pulmonary therapy often benefit from PPI trial.<\/p>\n Dental erosion.<\/strong> Chronic acid exposure dissolves tooth enamel, particularly on lingual surfaces. A dentist may be the first to suggest GERD evaluation.<\/p>\n Sleep disruption.<\/strong> Nocturnal reflux fragments sleep, often without the patient consciously waking. Patients describe being tired despite long sleep hours.<\/p>\n Chest pain.<\/strong> GERD is a top cause of non-cardiac chest pain after cardiac causes are excluded. Esophageal pain receptors share neural pathways with cardiac receptors, producing genuinely cardiac-feeling discomfort.<\/p>\n The diagnostic challenge with atypical GERD is that classic heartburn may be absent. Up to 40% of patients with reflux laryngitis don’t report typical heartburn. Empiric PPI trials of 12 weeks at twice-daily dosing are reasonable for suspected atypical GERD.<\/p>\n Key Takeaway: Singh’s 2013 meta-analysis found 10% body weight loss produces meaningful reflux symptom improvement.<\/p>\n Not all heartburn is GERD.<\/strong> The Lyon Consensus framework distinguishes:<\/p>\n True GERD:<\/strong> Objective evidence of pathologic acid exposure (AET over 6%) plus symptoms.<\/p>\n Reflux hypersensitivity:<\/strong> Normal acid exposure but symptoms triggered by physiologic reflux events. The esophagus is essentially over-sensitized.<\/p>\n Functional heartburn:<\/strong> Heartburn-type symptoms with normal acid exposure and no symptom-reflux correlation. The cause is centralized pain processing rather than peripheral reflux.<\/p>\n These distinctions matter because functional heartburn doesn’t respond to acid suppression. Patients can take PPIs for years without benefit. Treatments for functional heartburn include neuromodulators (low-dose tricyclic antidepressants, SSRIs), cognitive behavioral therapy, and hypnotherapy.<\/p>\n If you’ve been on appropriate PPI therapy for 12+ weeks without benefit, functional heartburn is on the differential. Objective testing distinguishes the categories.<\/p>\n Pregnancy.<\/strong> GERD prevalence rises dramatically during pregnancy, peaking in the third trimester at roughly 50%. Hormonal effects (progesterone relaxes the LES) plus mechanical pressure from the uterus drive symptoms. Most resolves postpartum. Treatment progression: lifestyle, then antacids, then H2RAs (famotidine has the most safety data), then PPIs (omeprazole has substantial data) for refractory disease.<\/p>\n Pediatric.<\/strong> GER (without the disease) is normal in infants and usually resolves by age 1. GERD in older children and adolescents follows similar patterns to adults but with attention to growth and feeding. Obesity-related pediatric GERD is increasing.<\/p>\n Roughly 30% of GERD patients have visible esophagitis at endoscopy.<\/strong> The remaining 70% have non-erosive reflux disease (NERD), where the esophagus looks normal despite real symptoms.<\/p>\n Endoscopic findings range from:<\/p>\n The absence of visible esophagitis doesn’t rule out GERD. Many NERD patients have positive pH testing and respond to acid suppression.<\/p>\n GERD treatment cost varies widely:<\/p>\n Insurance coverage varies for procedures. Generic PPIs are widely affordable. The economics often favor weight loss interventions when they reduce long-term medication needs.<\/p>\n Roughly a third of GERD patients have symptoms beyond classic heartburn.<\/strong> These atypical presentations are often missed for years because patients and clinicians don’t connect the dots.<\/p>\n Chronic cough.<\/strong> GERD is one of the top three causes of chronic cough in adults, alongside asthma and postnasal drip. The cough is often dry, worse at night or after meals, and doesn’t respond to typical cough treatments. Empiric PPI trial of 8 to 12 weeks is a reasonable diagnostic and therapeutic step.<\/p>\n Hoarseness and laryngitis.<\/strong> Reflux of acidic and non-acidic gastric contents into the larynx can cause chronic hoarseness, throat clearing, and sensation of a lump in the throat (globus). ENT evaluation often shows posterior laryngitis on laryngoscopy. The association is real but not every laryngitis is reflux-related.<\/p>\n Asthma.<\/strong> GERD worsens asthma in many patients, and asthma medications can worsen GERD. Patients with poorly-controlled asthma despite optimal pulmonary therapy often benefit from a PPI trial.<\/p>\n Dental erosion.<\/strong> Chronic acid exposure dissolves tooth enamel, particularly on lingual surfaces. A dentist may be the first to suggest GERD evaluation.<\/p>\n Sleep disruption.<\/strong> Nocturnal reflux fragments sleep, often without the patient consciously waking. Patients describe being tired despite long sleep hours.<\/p>\n Chest pain.<\/strong> GERD is a top cause of non-cardiac chest pain after cardiac causes are excluded. Esophageal pain receptors share neural pathways with cardiac receptors, producing genuinely cardiac-feeling discomfort.<\/p>\n The diagnostic challenge with atypical GERD is that classic heartburn may be absent. Up to 40% of patients with reflux laryngitis don’t report typical heartburn. Empiric PPI trials of 12 weeks at twice-daily dosing are reasonable for suspected atypical GERD.<\/p>\n Not all heartburn is GERD.<\/strong> The Lyon Consensus framework distinguishes:<\/p>\n True GERD:<\/strong> Objective evidence of pathologic acid exposure (AET over 6%) plus symptoms.<\/p>\n Reflux hypersensitivity:<\/strong> Normal acid exposure but symptoms triggered by physiologic reflux events. The esophagus is essentially over-sensitized.<\/p>\n Functional heartburn:<\/strong> Heartburn-type symptoms with normal acid exposure and no symptom-reflux correlation. The cause is centralized pain processing rather than peripheral reflux.<\/p>\n These distinctions matter because functional heartburn doesn’t respond to acid suppression. Patients can take PPIs for years without benefit. Treatments for functional heartburn include neuromodulators (low-dose tricyclic antidepressants, SSRIs), cognitive behavioral therapy, and hypnotherapy.<\/p>\n If you’ve been on appropriate PPI therapy for 12+ weeks without benefit, functional heartburn belongs on the differential. Objective testing distinguishes the categories.<\/p>\n GERD prevalence rises dramatically during pregnancy, peaking in the third trimester at roughly 50%.<\/strong> Hormonal effects (progesterone relaxes the LES) plus mechanical pressure from the uterus drive symptoms. Most resolves postpartum. Treatment progression: lifestyle, then antacids, then H2RAs (famotidine has the most safety data), then PPIs (omeprazole has substantial data) for refractory disease.<\/p>\n In children, gastroesophageal reflux without the disease is normal in infants and usually resolves by age 1. GERD in older children and adolescents follows similar patterns to adults but with attention to growth and feeding. Obesity-related pediatric GERD is increasing.<\/p>\n Roughly 30% of GERD patients have visible esophagitis at endoscopy.<\/strong> The remaining 70% have non-erosive reflux disease (NERD), where the esophagus looks normal despite real symptoms.<\/p>\n Endoscopic findings range from:<\/p>\n The absence of visible esophagitis doesn’t rule out GERD. Many NERD patients have positive pH testing and respond to acid suppression.<\/p>\n GERD treatment cost varies widely:<\/p>\n Insurance coverage varies for procedures. Generic PPIs are widely affordable. The economics often favor weight loss interventions when they reduce long-term medication needs.<\/p>\n Bottom line: Long-term, weight loss often reduces or eliminates the need for daily PPIs.<\/p>\n Misconceptions about treatment can delay good decisions. Here are three worth correcting before you make any choices about your care.<\/p>\n Myth:<\/strong> GLP-1 medications always make GERD worse. Fact:<\/strong> Slowed gastric emptying can increase reflux for some patients, but the weight loss benefit often improves GERD overall. Net effect varies. Lim 2024 systematic review showed mixed but mostly favorable outcomes.<\/p>\n Myth:<\/strong> PPIs are dangerous to take long term. Fact:<\/strong> Most concerns about long-term PPI use come from observational studies with weak causal links. Real risks (B12 absorption, occasional kidney effects) are manageable with monitoring. For erosive esophagitis or Barrett’s esophagus, the benefits clearly outweigh the risks.<\/p>\n Myth:<\/strong> Apple cider vinegar fixes acid reflux. Fact:<\/strong> There’s no good evidence that apple cider vinegar improves GERD, and adding more acid to an already acidic stomach is the opposite of what physiology suggests. Skip the wellness shelf and try the evidence-based options.<\/p>\n Managing your metabolic health shouldn’t be a journey you take alone. The science behind GLP-1 medications offers a new level of hope for people facing acid reflux and the related challenges that come with it. By addressing root hormonal and metabolic causes, these treatments provide a path toward more stable energy, better cardiovascular health, and improved quality of life.<\/p>\n At TrimRx, we’re committed to providing an empathetic and transparent experience. We understand the frustrations of traditional healthcare: the long waits, the unclear costs, and the lack of personalized care. Our platform is designed to put you back in control of your health. By combining clinical expertise with modern technology, we help you access the treatments you need while providing the 24\/7 support you deserve.<\/p>\n Our program includes:<\/p>\n Sustainable health is about more than a number on a scale or a single lab result. It’s about feeling empowered in your own body. Whether you’re starting to research your options or ready to take the next step with a free assessment, we’re here to guide you with science-backed, personalized care.<\/p>\n Bottom line:<\/strong> TrimRx provides a streamlined, medically supervised path to access the latest advancements in acid reflux and weight management, all from the comfort of home.<\/p>\n For many people with obesity-driven reflux, yes. Singh’s 2013 meta-analysis showed that 10% body weight loss produces significant symptom and acid-exposure improvements. Patients who lose more often discontinue daily PPIs entirely. Cure is the wrong word for some, since hiatal hernias and LES dysfunction may persist, but symptom resolution is achievable.<\/p>\n They can in the short term. GLP-1s slow gastric emptying, which means food sits in the stomach longer and is more available for reflux. New or worsened heartburn is a known side effect. Over time, the weight loss usually outweighs the gastric retention effect, and many patients see net improvement.<\/p>\n Heartburn is a symptom, the burning chest sensation. GERD is the chronic disease defined by frequent reflux causing symptoms or tissue damage. Occasional heartburn after a heavy meal isn’t GERD. Heartburn twice a week or more, especially with regurgitation or other symptoms, usually is.<\/p>\n There’s no firm cutoff. Long-term use carries some risks (B12, magnesium, modest infection risk), but for most patients with confirmed GERD or Barrett’s, benefits outweigh those risks. The right approach is periodic reassessment and stepping down to the lowest effective dose, not arbitrary stopping.<\/p>\n Not everyone needs one. The ACG recommends endoscopy for alarm symptoms (trouble swallowing, weight loss, anemia, GI bleeding, persistent vomiting), refractory symptoms despite PPI therapy, or chronic GERD with Barrett’s risk factors. Garden-variety heartburn that responds to lifestyle and OTC medication usually doesn’t need endoscopy.<\/p>\n For most patients with obesity and GERD, Roux-en-Y gastric bypass is excellent for reflux control. It diverts acid-producing stomach away from the esophagus. Sleeve gastrectomy, the other common bariatric procedure, often worsens GERD and isn’t usually recommended for patients with significant baseline reflux.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Gastroesophageal reflux disease affects roughly 1 in 5 American adults every week, and that number rises sharply with body weight.<\/p>\n","protected":false},"author":11,"featured_media":76486,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[12],"tags":[],"class_list":["post-76487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/76487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=76487"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/76487\/revisions"}],"predecessor-version":[{"id":76754,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/76487\/revisions\/76754"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/76486"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=76487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=76487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=76487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}How Common Is GERD?<\/h3>\n
How GERD Actually Works<\/h2>\n
Why Obesity Causes GERD<\/h2>\n
\n
Does Weight Loss Actually Improve GERD?<\/h2>\n
What About GLP-1 Medications?<\/h2>\n
First-line GERD Treatments<\/h2>\n
Lifestyle Changes<\/h3>\n
\n
Medications<\/h3>\n
Are PPIs Safe Long Term?<\/h2>\n
\n
\n
When Is Surgery Appropriate?<\/h2>\n
Barrett’s Esophagus and Cancer Risk<\/h2>\n
\n
Putting It All Together<\/h2>\n
\n
Atypical and Extraesophageal GERD<\/h2>\n
Functional Heartburn and Reflux Hypersensitivity<\/h2>\n
Pediatric and Pregnancy Considerations<\/h2>\n
Endoscopic Findings in GERD<\/h2>\n
\n
Cost and Practical Considerations<\/h2>\n
\n
Atypical and Extraesophageal GERD<\/h2>\n
Functional Heartburn and Reflux Hypersensitivity<\/h2>\n
Pregnancy and Pediatric Considerations<\/h2>\n
Endoscopic Findings in GERD<\/h2>\n
\n
Cost and Practical Considerations<\/h2>\n
\n
Myth vs. Fact: Setting the Record Straight<\/h2>\n
The Path Forward with TrimRx<\/h2>\n
\n
FAQ<\/h2>\n
Can Losing Weight Cure GERD?<\/h3>\n
Do GLP-1 Medications Cause Acid REFLUX?<\/h3>\n
What’s the Difference Between Heartburn and GERD?<\/h3>\n
How Long Can I Safely Take a PPI?<\/h3>\n
Should I Get an Endoscopy for My REFLUX?<\/h3>\n
Will Gastric Bypass Fix My GERD?<\/h3>\n